替罗非班在急性心肌梗死支架置入术中的应用

目的观察急性心肌梗死支架置入术中冠脉内应用血小板糖蛋白（GP）Ⅱb／Ⅲa受体拮抗剂盐酸替罗非班的疗效和安全性。方法64例急性心肌梗死患者随机分为2组，冠状动脉内置入支架加替罗非班组34例,冠状动脉内置入支架加用普通肝素组30例，均于发病12h内行急诊PCI术。观察两组患者用药后对冠状动脉再灌注的影响，并随访主要心脑血管事件和出血并发症。结果替罗非班组PCI术后慢复流发生率及主要不良心脏事件的发生率均低于普通肝素组，差异有统计学意义（P〈0．05），出血并发症的发生与普通肝素组差异无统计学意义（P〈0．05）。结论冠状动脉内应用替罗非班能改善急性心肌梗死患者支架置入术后梗死相关血管的TIMI血流，减少PCI术后主要不良心脏事件的发生率，临床应用安全有效。

Application of Tirofiban in Percutaneous Coronary Intervention for Actuemyocardial Infarction Patients

Objective To evaluate the safety and efficacy of tirofiban in pereutaneous coronary interention （PCI） for acute myocardial infarction （AMI）. Methods 80 AMI patients were randomly divided into two groups： the tirofiban group （n = 34） and the control group （n = 30）. All the individuals were performed PCI within 12 hours after onest of AMI. All the test group individuals were injected Tirofiban （10mg） into the infarction related artery （IRA） during PCI and intravenously adminstered Tirefiban 36 hours （0. 15μg/kg. min） after PCI. The control group only receive routine intravenous heparin therapy before and during PCI. The post operation TIMI blood flow, bleeding events and major adverse cardiac events were observed in the 2 groups. Results In tirofiban group, the occuranee of slow - reflow and The major adverse cardiac events were lower than those in control group, The oceuranee of bleeding complication In Tirofiban group was the same as those in control group, there was no significant difference in both groups. Conclusion Application of Tiortlban intracoronary injection during primary PCIin patients with AMI was safe and effective, which may reduce the occurrence of the major adverse cardiac events, and improve TIMI flow of IRA in patients with AMI during primary PCI.